Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis

Mirko Dengler¹,*, Katharina Stauffer²,¹²,*, Heidemarie Huber¹, Rudolf Stauber³, Heike Bantel⁴, Karl Heinz Weiss⁶, Patrick Starlinger⁶, Hannelore Pock³, Petra Klöters-Plachky⁵, Daniel N. Gotthardt⁶, Peter Rauch⁷, Carolin Lackner⁸, Judith Stift⁹, Christine Brostjan⁶, Thomas Gruenberger⁶, Takashi Kumada¹⁰, Hidenori Toyoda¹⁰, Toshifumi Tada¹⁰, Thomas S. Weiss¹¹, Michael Trauner¹² and Wolfgang Mikulits¹

¹Department of Medicine I, Institute of Cancer Research, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria
²Department of Surgery, Division of Transplantation, Medical University of Vienna, Vienna, Austria
³Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
⁴Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
⁵University Hospital Heidelberg, Heidelberg, Germany
⁶Department of Surgery, Division of General Surgery, Medical University of Vienna, Vienna, Austria
⁷Candor Bioscience GmbH, Wangen im Allgäu, Germany
⁸Institute of Pathology, Medical University of Graz, Graz, Austria
⁹Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria
¹⁰Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan
¹¹Center for Liver Cell Research, Children’s University Hospital (KUNO), University of Regensburg Hospital, Regensburg, Germany
¹²Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria

*These authors have contributed equally to this work

Correspondence to: Wolfgang Mikulits, email: wolfgang.mikulits@meduniwien.ac.at

Keywords: soluble Axl, biomarker, fibrosis, cirrhosis, hepatocellular carcinoma

Received: September 01, 2016 Accepted: April 06, 2017 Published: May 03, 2017

ABSTRACT

Patients with chronic liver disease (CLD) and cirrhosis are at high risk for hepatocellular carcinoma (HCC). Current diagnostic tools for HCC detection include imaging techniques and serum biomarkers such as α-fetoprotein (AFP). Yet, these methods are limited in sensitivity and specificity to accurately detect early HCC. Here we focused on the potential of soluble Axl (sAxl) as a biomarker in CLD patients by analyzing serum samples of 1067 patients and healthy controls from centers in Europe and Asia. We show that serum concentrations of sAxl were significantly increased at early (82.57 ng/mL) and later stages of HCC (114.50 ng/mL) as compared to healthy controls (40.15 ng/mL). Notably, no elevated sAxl levels were detected in patients with CLD including chronic viral hepatitis, autoimmune hepatitis, cholestatic liver disease, or non-alcoholic fatty liver disease versus healthy controls. Furthermore, sAxl did not rise in liver adenomas or cholangiocarcinoma (CCA). Yet, patients with advanced fibrosis (F3) or cirrhosis (F4) showed enhanced sAxl concentrations (F3: 54.67 ng/mL; F4: 94.74 ng/mL). Hepatic myofibroblasts exhibited an increased release of sAxl,
sAxl was significantly higher in HCC patients than in patients with liver cirrhosis only, suggesting that sAxl is a promising diagnostic biomarker for routine clinical use.

In the present large scale multicenter study, we analyzed sAxl levels in sera from 1067 participants suffering from HCC in cirrhotic and non-cirrhotic patients, cholangiocarcinoma (CCA), liver adenoma, and various CLDs with zero to advanced liver fibrosis and cirrhosis. Importantly, this setting allowed us to assess the diagnostic performance of sAxl for HCC in comparison to other solid liver tumors and liver diseases. Furthermore, we were able to determine the accuracy of sAxl in mild to advanced stages of CLD, demonstrating the potential diagnostic value of sAxl for routine clinical use in surveillance of patients at high risk for HCC.

RESULTS

High diagnostic value of sAxl for HCC

We assessed serum levels of sAxl by ELISA in 347 HCC patients and 75 healthy controls from different centers and etiologies (Supplementary Figure 1, Tables 1 and 2). HCC patients were grouped according to liver disease etiology, fibrosis grades, presence or absence of cirrhosis, and BCLC stage (Tables 1 and 2). All HCC patients showed significantly increased median sAxl levels (78.69 ng/mL) in comparison to healthy controls (40.15 ng/mL), independent of the presence of cirrhosis, i.e. 83.37 ng/mL with cirrhosis versus 61.92 ng/mL without cirrhosis (Figure 1A, Table 2). Additional stratification of HCC patients according to BCLC criteria revealed enhanced sAxl levels in early (82.57 ng/mL) but also in intermediate (73.46 ng/mL), advanced (77.08 ng/mL) and end-stage HCC (114.50 ng/mL) as compared to healthy controls (Figure 1B, Table 2). The increase in BCLC D was significant when compared to BCLC A (p = 0.0106), BCLC B (p = 0.0012) and BCLC C (p = 0.0005). Interestingly, HCC patients with cirrhosis had significantly higher sAxl levels in comparison to HCC patients without cirrhosis (Figure 1C, Table 2). From these data we concluded that sAxl accurately detects HCC without cirrhosis as well as HCC in the background of cirrhosis, the latter with higher levels.

Detection of advanced fibrosis and cirrhosis by sAxl independently of liver disease etiology

We next compared median sAxl levels according to the stage of fibrosis (fibrosis [F] grades 0-4). We could observe significantly increased sAxl levels in advanced...
Table 1: Demographic and clinicopathological attributes of HCC study population

| Variable               | Number of cases | %    | Valid % |
|------------------------|-----------------|------|---------|
| **Age (years)**        |                 |      |         |
| Valid                  |                 |      |         |
| < 55                   | 26              | 7.5  | 8.2     |
| ≥ 55                   | 293             | 84.4 | 91.8    |
| Missing                | 28              | 8.1  |         |
| Total                  | 347             | 100.0| 100.0   |
| **Sex**                |                 |      |         |
| Valid                  |                 |      |         |
| Male                   | 193             | 55.6 | 82.8    |
| Female                 | 40              | 11.5 | 17.2    |
| Missing                | 114             | 32.9 |         |
| Total                  | 347             | 100.0| 100.0   |
| **HBV Status**         |                 |      |         |
| Valid                  |                 |      |         |
| Negative               | 133             | 38.3 | 88.1    |
| Positive               | 18              | 5.2  | 11.9    |
| Missing                | 196             | 56.5 |         |
| Total                  | 347             | 100.0| 100.0   |
| **HCV Status**         |                 |      |         |
| Valid                  |                 |      |         |
| Negative               | 113             | 32.6 | 74.8    |
| Positive               | 38              | 11.0 | 25.2    |
| Missing                | 196             | 56.5 |         |
| Total                  | 347             | 100.0| 100.0   |
| **Cirrhosis**          |                 |      |         |
| Valid                  |                 |      |         |
| Negative               | 35              | 10.1 | 11.4    |
| Positive               | 272             | 78.4 | 88.6    |
| Missing                | 40              | 11.5 |         |
| Total                  | 347             | 100.0| 100.0   |
| **Vascular invasion**  |                 |      |         |
| Valid                  |                 |      |         |
| Negative               | 76              | 21.9 | 36.2    |
| Positive               | 134             | 38.6 | 63.8    |
| Missing                | 137             | 39.5 |         |
| Total                  | 347             | 100.0| 100.0   |
| **Lymph node metastasis** |             |      |         |
| Valid                  |                 |      |         |
| Negative               | 174             | 50.1 | 91.6    |
| Positive               | 16              | 4.6  | 8.4     |
| Missing                | 157             | 45.2 |         |
| Total                  | 347             | 100.0| 100.0   |

HBV: hepatitis B virus; HCV: hepatitis C virus.
fibrosis (F3: 54.67 ng/mL) and cirrhosis (F4: 94.74 ng/mL) when compared to healthy controls (40.15 ng/mL), no fibrosis (F0: 40.70 ng/mL), mild (F1: 46.20 ng/mL) or moderate fibrosis (F2: 46.76 ng/mL) (Figure 2A, Table 2). Interestingly, the cirrhosis patients showed significantly enhanced sAxl levels as compared to advanced fibrosis (Figure 2A and 2B). Notably, all fibrosis stages were significantly lower than HCC, however, the cirrhosis group showed increased sAxl values, respectively (Figure 2B, Table 2). Furthermore, HCC without cirrhosis

*347 HCC samples in total, including information for dedicated numbers of cirrhosis status and BCLC stages. Respective clinical data were not available for all 347 HCC cases.

HCC: hepatocellular carcinoma; BCLC: Barcelona clinic liver cancer staging; CCA: cholangiocellular carcinoma; AIH: autoimmune hepatitis; NAFLD: non-alcoholic fatty liver disease; AFP: α-fetoprotein; IQR: interquartile range.

Table 2: sAxl and AFP serum concentrations of the study population

| Number of cases | Median (IQR) ng/mL |
|-----------------|-------------------|
| **sAxl**        |                   |
| Healthy controls| 75                | 40.15 (35.22 - 46.85) |
| Tumors patients:|                   |                   |
| All HCC         | 347*              | 78.69 (55.09 - 101.5) |
| HCC with cirrhosis| 272              | 83.37 (62.13 - 107.1) |
| HCC w/o cirrhosis| 35               | 61.92 (43.13 - 81.09) |
| BCLC A          | 45                | 82.57 (52.13 - 110.2) |
| BCLC B          | 45                | 73.46 (50.59 - 87.24) |
| BCLC C          | 67                | 77.08 (55.09 - 96.33) |
| BCLC D          | 12                | 114.50 (89.69 - 134.6) |
| CCA             | 44                | 41.02 (33.89 - 48.11) |
| Adenoma         | 11                | 31.41 (25.95 - 36.57) |
| Chronic liver diseases | 400            |                   |
| Fibrosis stages:|                   |                   |
| F0              | 54                | 40.70 (35.56 - 51.98) |
| F1              | 75                | 46.20 (38.64 - 55.07) |
| F2              | 80                | 46.76 (40.37 - 60.06) |
| F3              | 36                | 54.67 (43.45 - 74.92) |
| F4 (cirrhosis w/o HCC) | 155           | 94.74 (66.38 - 132.5) |
| Liver disease etiology:|               |                   |
| Viral hepatitis | 26                | 47.87 (42.30 - 61.75) |
| AIH             | 18                | 48.40 (36.16 - 84.20) |
| Cholestatic liver disease | 30              | 40.97 (36.01 - 51.06) |
| NAFLD           | 116               | 43.15 (37.72 - 53.85) |
| **AFP**         |                   |                   |
| Healthy controls| 28                | 2.60 (1.500 - 3.475) |
| All HCC         | 274               | 12.90 (5.275 - 173.3) |
| HCC with cirrhosis| 194              | 11.50 (0 - 49.33)   |
| HCC w/o cirrhosis| 28               | 23.60 (3.900 - 4743) |
| F4 (cirrhosis w/o HCC) | 24               | 4.65 (3.025 - 6.650) |

*347 HCC samples in total, including information for dedicated numbers of cirrhosis status and BCLC stages. Respective clinical data were not available for all 347 HCC cases.

HCC: hepatocellular carcinoma; BCLC: Barcelona clinic liver cancer staging; CCA: cholangiocellular carcinoma; AIH: autoimmune hepatitis; NAFLD: non-alcoholic fatty liver disease; AFP: α-fetoprotein; IQR: interquartile range.
(61.92 ng/mL) showed higher levels of sAxl as compared to F3 fibrosis (54.67 ng/mL), yet without statistical significance (Table 2).

Moreover, we examined sAxl levels in patients with CLD of different etiology. Notably, analysis of patient sera from non-cirrhotic viral hepatitis (chronic hepatitis B or C; 47.87 ng/mL), autoimmune hepatitis (AIH, 48.40 ng/mL), cholestatic liver disease (40.97 ng/mL) and non-alcoholic fatty liver disease (NAFLD; 43.15 ng/mL) showed median concentrations of sAxl similar to healthy controls, but displayed significant differences to HCC patient samples (Figure 2C-2F, Table 2). Importantly, no significant changes in serum sAxl were detected in cholangiocarcinoma (CCA; 41.02 ng/mL) and liver adenoma (31.41 ng/mL) patients versus healthy controls. Additionally, these results were significantly different to sAxl levels in patients with HCC (Figure 3A and 3B, Table 2). Together, these data revealed that patients with CLD, independent of etiology, fail to show increased sAxl levels in the absence of advanced fibrosis/cirrhosis, while large cohorts of patients with F3/F4 fibrosis display elevated levels of sAxl. Liver tumors such as benign liver adenomas or CCA show no alterations in sAxl levels.

**Cut-off levels of sAxl in detecting HCC and cirrhosis**

Next we investigated the diagnostic value of sAxl in HCC and cirrhosis with and without incorporation of the established serum marker AFP. ROC curve analysis and the area under the curve (AUC) revealed a high diagnostic performance of sAxl for HCC (AUC 0.903) and also cirrhosis (AUC 0.935) (Figure 4A and 4B). In detail, sAxl displayed a sensitivity of 83.3% and specificity of 86.7% in HCC at a cut-off of 49.71 ng/mL. For cirrhosis, sAxl showed a sensitivity of 80.8% and a specificity of 92.0%
Figure 2: sAxl levels in fibrosis and CLDs. (A) sAxl serum concentrations in healthy controls (n = 75) compared to patients without fibrosis (F0: n = 54), with mild fibrosis (F1: n = 75), moderate fibrosis (F2: n = 80), advanced fibrosis (F3: n = 36) and cirrhosis (F4: n = 155). (B) sAxl serum levels of all HCC patients (n = 347) versus fibrosis and cirrhosis patients. (C) sAxl serum concentrations in healthy controls (n = 75) compared to patients with viral hepatitis (n = 26), and autoimmune hepatitis (AIH: n = 18). (D) sAxl serum levels of all HCC patients versus viral hepatitis and AIH patients. (E) Analysis of sAxl serum concentrations in healthy controls (n = 75), cholestatic liver disease (n = 30) and patients with non-alcoholic fatty liver disease (NAFLD; n = 116). (F) Statistical comparison between all HCC patients (n = 347) to cholestatic liver disease patients and NAFLD. Serum samples were diluted with LowCross-buffer® (Candor, Germany) 1:200 and analyzed for sAxl levels by ELISA. Horizontal bars indicate median levels with interquartile ranges. Statistical significances of the differences between groups were evaluated with Mann-Whitney U test. Ns: not significant. ** p ≤ 0.01, *** p ≤ 0.001.
Figure 3: sAxl levels in CCA and liver adenoma patients. (A) Analysis of sAxl serum concentrations in healthy controls ($n$ = 75), CCA patients ($n$ = 44) and patients with benign liver adenoma ($n$ = 11). (B) Statistical comparison between all HCC patients to CCA and adenoma patients. Serum samples were diluted with LowCross-buffer® (Candor, Germany) 1:200 and analyzed for sAxl levels by ELISA. Horizontal bars indicate median levels with interquartile ranges. Statistical significances of the differences between groups were evaluated with Mann-Whitney U test. Ns: not significant. *** $p \leq 0.001$.

Figure 4: Detection of HCC and cirrhosis by sAxl. (A) ROC curve of sAxl in healthy controls ($n$ = 75) versus HCC ($n$ = 347). (B) ROC curve of sAxl in healthy controls ($n$ = 75) versus cirrhosis (F4, cirrhosis w/o HCC; $n$ = 155). (C) ROC curve of sAxl, AFP and a combination of both in healthy controls ($n$ = 28) versus HCC patients ($n$ = 274). (D) ROC curve of sAxl, AFP and a combination of both in healthy controls ($n$ = 28) versus cirrhosis patients (F4, cirrhosis w/o HCC; $n$ = 24). Numbers in parentheses represent area under the curve.
at a cut-off of 54.0 ng/mL (Table 3). Interestingly, sAxl outperformed AFP in diagnostic performance in both HCC and cirrhosis. In HCC, sAxl exhibited high sensitivity (74.4%) at the optimal cut-off of 60.42 ng/mL compared to AFP (38.8%) at its cut-off of 20 ng/mL. To evaluate the combination of both markers, we calculated the predicted probability by binary logistic regression. The combination of sAxl and AFP, further exceptionally increased the accuracy (0.947) and sensitivity (86.9%), respectively (Figure 4C, Table 3). The specificity for detection of HCC was 100% for each marker alone and in combination (Table 3). Additionally, in cirrhosis sAxl sensitivity was tremendously high (100%) at a cutoff of 54.47 ng/mL. For AFP we could not depict a clinical valuable cutoff, and therefore AFP showed an intermediate sensitivity of 70.8% at a cutoff of 3.65 ng/mL. This cut-off involved a lot of healthy subjects as well. Here, the combination of sAxl and AFP increased the accuracy (0.993) and slightly decreased the sensitivity (95.8%) as compared to sAxl alone (Figure 4D, Table 3).

Next, we assessed the diagnostic probabilities of sAxl in detecting HCC with and without cirrhosis, advanced fibrosis (F3) alone and in combination with cirrhosis. For HCC with cirrhosis, we obtained a remarkable AUC of 0.929 accompanied by a high sensitivity of 89.0% and specificity of 86.7% (Supplementary Figure 2A, Table 3). Single and combinational assessment of sAxl and AFP disclosed a better AUC of 0.937 for sAxl then for AFP (0.855) in HCC patients with cirrhosis. Also the sensitivity was tremendously better for sAxl (80.4%) as compared to AFP (32.5%). Again, the combination of both markers further increased the AUC (0.954), the sensitivity (84.0%) and specificity (100%) (Supplementary Figure 2B, Table 3). By evaluating the results of HCC patients without liver cirrhosis, we were able to reach an accuracy of 0.789 with a sensitivity of 54.3% and a specificity of 96.0% (Supplementary Figure 2C, Table 3). Results of HCC without cirrhosis including both markers revealed a better AUC for AFP (0.828) as compared to sAxl (0.804) alone, but sAxl showed higher sensitivity (60.7%) and specificity (96.4%) than AFP alone (sensitivity: 53.6%; specificity 100%). Remarkably, the combination of both markers revealed a great accuracy (0.941), sensitivity (85.7%) and specificity (96.4%) of detecting non-cirrhotic HCC (Supplementary Figure 2D, Table 3). Similar results were obtained for advanced fibrosis with an AUC of 0.810, sensitivity of 72.0% and specificity of 89.3% (Supplementary Figure 2E, Table 3). By pooling the results of patients suffering on either advanced fibrosis (F3) or cirrhosis, we reached an AUC of 0.918 resulting in a sensitivity of 82.7% and a specificity of 92.0% compared to advanced fibrosis alone (AUC 0.810) (Supplementary Figure 2E and 2F, Table 3). Overall, these results confirmed the assumption that cirrhosis plays an important role on sAxl levels in serum. The diagnostic performance of sAxl in detecting HCC (Vienna, AUC 0.781; Graz, AUC 0.885; Heidelberg, AUC 0.925; Hannover, AUC 0.932; Ogaki, AUC 0.934) and cirrhosis (Vienna, AUC 0.855; Graz, AUC 0.987; Hannover, AUC 0.977) was high across all centers included in this study (Supplementary Figures 3 and 4, Table 3).

**Cellular sources of sAxl during advanced fibrosis and cirrhosis**

As recently reported, we showed that mesenchymal HCC cell lines release high levels of sAxl whereas epithelial HCC cell lines fail to release sAxl [23]. Here, we confirmed these data, and additionally found that CCA cell lines show only modest release of sAxl, which is in accordance with low sAxl levels in sera of CCA patients (Figure 3A and 3B). Furthermore, we investigated the sAxl release of liver myofibroblasts and observed a strong sAxl release by most of these cell lines which are generally associated with fibrosis progression (Figure 5) [25-28]. These data suggest that sAxl is predominantly released by myofibroblasts which accumulate during increased fibrosis.

**DISCUSSION**

The present study evaluated the diagnostic performance of sAxl for the detection of early HCC and patients at high risk of HCC in a large multicentric cohort of 1067 patients. In comparison with healthy controls, sAxl showed a high diagnostic accuracy for the detection of HCC in patients with (AUC 0.929) and without cirrhosis (AUC 0.789). However, sAxl was additionally identified as an excellent marker of advanced fibrosis (F3; AUC 0.810) and cirrhosis (F4; AUC 0.935). Diagnostic accuracy was further improved, if both sAxl and AFP were combined (HCC with cirrhosis: AUC 0.947; HCC w/o cirrhosis: AUC 0.941; cirrhosis: AUC 0.993). Recently, we reported a high accuracy of sAxl in the diagnosis of early as well as advanced stages of HCC [24]. The diagnostic value of sAxl for early HCC (BCLC A) and all other BCLC stages of HCC was confirmed in the present study (Figure 1B). sAxl levels were BCLC stage-dependent, since patients with BCLC stage D showed significantly elevated sAxl levels in comparison to BCLC A, B, or C, and healthy controls. Of note, sAxl was not only significantly elevated in patients with HCC and cirrhosis in the present study, but also in patients with HCC without cirrhosis (Figure 1A) as compared to healthy controls. This may lead to the assumption, that sAxl accurately detects HCC, both in the presence as well as in the absence of liver cirrhosis. However, no significant difference in sAxl levels was found when (i) patients with HCC and cirrhosis were compared to patients with HCC but without cirrhosis or cirrhosis without HCC (Supplementary Figure 5), and (ii), when HCC patients...
Table 3: Performance of sAxl and AFP in the detection of HCC and chronic liver diseases

| Sample size | AUC (95% CI) | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | Youden’s index | Cut-off (ng/mL) |
|-------------|--------------|----------------|-----------------|---------|---------|----------------|----------------|
| sAxl        |              |                |                 |         |         |                |                 |
| HCC vs. HC  | 347 vs. 75   | 0.903 (0.873 - 0.932) | 83.3 | 86.7 | 96.7 | 52.9 | 0.70 | 49.71 |
| HCC with cirrhosis vs. HC | 272 vs. 75 | 0.929 (0.903 - 0.956) | 89.0 | 86.7 | 96.0 | 68.4 | 0.76 | 49.71 |
| HCC w/o cirrhosis vs. HC | 35 vs. 75 | 0.789 (0.688 - 0.891) | 54.3 | 96.0 | 86.4 | 81.8 | 0.50 | 58.39 |
| Cirrhosis vs. HC | 155 vs. 75 | 0.935 (0.909 - 0.961) | 80.8 | 92.0 | 97.1 | 59.5 | 0.79 | 54.0 |
| Fibrosis F3 vs. HC | 36 vs. 75 | 0.810 (0.687 - 0.933) | 72.0 | 89.3 | 69.2 | 90.5 | 0.61 | 52.86 |
| Fibrosis F3, cirrhosis vs. HC | 191 vs. 75 | 0.918 (0.885 - 0.950) | 82.7 | 92.0 | 96.3 | 67.7 | 0.75 | 53.89 |
| sAXL + AFP |              |                |                 |         |         |                |                 |
| HCC vs. HC  | 274 vs. 28   | 0.902 (0.865 - 0.939) | 74.4 | 100.0 | 100.0 | 28.0 | 0.74 | 60.42 |
| HCC with cirrhosis vs. HC | 194 vs. 28 | 0.937 (0.905 - 0.969) | 80.4 | 96.4 | 99.4 | 41.5 | 0.80 | 60.42 |
| HCC w/o cirrhosis vs. HC | 28 vs. 28 | 0.804 (0.682 - 0.925) | 60.7 | 96.4 | 94.4 | 71.1 | 0.57 | 61.07 |

(Continued)
without cirrhosis were compared to patients with CLD and fibrosis grade 3 without HCC. Yet, sAxl levels in fibrosis grades 0 to 2 were similar to levels in healthy controls. This means that sAxl is an excellent marker for advanced fibrosis or liver cirrhosis independently of the presence or absence of HCC.

This is contradictory to our previous published data showing a significant difference between 26 patients with very early HCC (BCLC 0) and 30 patients with liver cirrhosis [24]. In the present study, 155 patients with cirrhosis from different centers were included in the study and compared to 272 HCC patients with cirrhosis and 35 HCC patients without cirrhosis. Therefore, the divergent findings may result from a significantly lower case number in our previous study. A possible explanation for our results is that liver fibrosis, mainly characterized by the accumulation of extracellular matrix components derived from activated hepatic stellate cells (HSC), promotes an environment permissive for tumor development. HSCs transform during chronic liver injury from a quiescent state.
into a myofibroblast-like phenotype, which proliferate and migrate towards areas of necrosis and regeneration [29]. Our findings are also in line with a study recently published by Barcena et al showing that sAxl is involved in liver fibrosis progression [25]. In this study using HSCs obtained from wildtype and Axl<sup>-/-</sup> mice treated with recombinant Gas6, Axl siRNAs or the Axl inhibitor BGB324, the Gas6/Axl axis was reported to be required for HSC activation. Furthermore, Axl serum levels increased in parallel to CLD progression in line with our data demonstrating that sAxl levels are rising with increasing fibrosis stages (Figure 2A and 2B, Table 2). This was independent of liver disease etiology (Figure 2C-2F).

Our findings are further supported by the fact that 6 out of 7 liver myofibroblast cell lines under investigation showed a strong sAxl release, suggesting that sAxl is predominantly released by myofibroblasts during fibrosis progression (Figure 5). This may be explained by an increased proteolysis of Axl in myofibroblasts during fibrosis development, facilitating an HCC permissive state [30]. Moreover, sAxl was specific for HCC and liver fibrosis progression in all tested scenarios as sAxl was significantly elevated in HCC, but not in CLD without HCC, such as chronic viral hepatitis, AIH, cholestatic liver disease, and NAFLD (Figure 2C-2F). Additionally, sAxl levels in CCA and liver adenomas remained as low as in healthy controls (Figure 3A), and were therefore significantly lower than in HCC patients (Figure 3B).

As we reported in a previous manuscript, sAxl is also significantly higher in HCC than in other solid tumors, such as ovarian, breast and hepatic metastases of CRC [24].

Based on our present study, sAxl has an excellent diagnostic accuracy for the detection of advanced fibrosis/cirrhosis (AUC 0.918) and HCC at all stages (AUC 0.929) superior to AFP as well as has a favourable accuracy in HCC without cirrhosis (AUC 0.789) (Table 3). Nevertheless, measurement of sAxl alone may not enable clinicians to securely differentiate between advanced fibrosis/cirrhosis and early HCC.

Combining both sAxl and AFP, however, may further increase diagnostic accuracy. Recently, Jang et al compared the diagnostic accuracy of 4 HCC biomarkers alone and in combination (AFP, osteopontin, DKK-1 and protein induced by vitamin K absence (PIVKA-II)) in 208 HCC patients and 193 liver cirrhotic control patients from Korea [31]. Of all tested biomarkers, AFP performed best for the detection of early HCC at a cut-off of 20 ng/mL (AUC: 0.678, sensitivity: 45.2%, specificity: 90.2%). The best performing combination of biomarkers was AFP plus DKK-1 (cut-off: 500 pg/mL) reaching an AUC of 0.693 (sensitivity: 66.0%, specificity: 72.5%). Further studies investigated the combination of annexin A2 and AFP (combined AUC 0.83) or thioredoxin and AFP (combined AUC 0.88) achieving even higher diagnostic accuracy [15, 32, 33]. In our study, the combination of
AFP (cut-off of ≥ 20 ng/mL) and sAxl at a cutoff of ≥ 61 ng/mL reached excellent diagnostic accuracy with a sensitivity and specificity of 84.0% and 100% for HCC with cirrhosis (AUC 0.954), and 85.7% and 96.4% for HCC without cirrhosis (AUC 0.941), respectively. Interestingly, our study further revealed a high diagnostic accuracy for the detection of HCC even in AFP-negative cases (AUC=0.790; sensitivity 71.0% and specificity 83.0%) when comparing all AFP-negative HCC patients (cut-off < 20 ng/mL AFP) with AFP-negative fibrosis/cirrhosis (F1-F4) patients (Supplementary Figure 6).

During the last update of the clinical practice guidelines 2012 of the European Association for the Study of the Liver, AFP was abandoned and diagnostic criteria are still based on imaging techniques and/or histopathology [7]. Nevertheless, many centers practice regular AFP measurements complementing imaging studies for HCC surveillance in cirrhotic patients. AFP, however, can only be taken into consideration in case it is elevated or shows an increase over time.

Owing to the large sample size and multicenter approach, detailed clinical data of patients were not available. Although our analysis includes a large cohort of study participants, patient numbers available for subgroup analysis are rather low and especially data on BCLC stages, different CLD and combination of AFP with sAxl should be confirmed in further series. In addition, our study cohort represents a cross sectional patient collective so that data on longitudinal courses of sAxl and AFP levels cannot be provided. In conclusion, sAxl is an excellent marker for advanced liver fibrosis/cirrhosis in most common CLDs and is specific for HCC. Used in combination with AFP, sAxl shows a high potential as an accurate surveillance marker in patients at high risk for HCC.

MATERIALS AND METHODS

Study population

Serum samples from patients with HCC (n = 347), intrahepatic CCA (n = 44), liver adenoma (n = 11), liver fibrosis (n = 245), liver cirrhosis (n = 155), and CLDs (n = 190) such as chronic infection with hepatitis B and hepatitis C virus (viral hepatitis), autoimmune hepatitis (AIH), primary biliary cirrhosis and primary sclerosing cholangitis (cholestatic liver disease) or non-alcoholic fatty liver disease (NAFLD) were collected from different centers in Europe and Asia. In addition, age-matched serum samples from healthy controls (n = 75) were included in the analysis. Samples were collected at the Medical University of Vienna (MUW) (Vienna, Austria; n = 416), Medical University Graz (Graz, Austria; n = 335), University of Regensburg Hospital (Regensburg, Germany; n = 21), University Hospital Heidelberg (Heidelberg, Germany; n = 119), Hannover Medical School (Hannover, Germany; n = 83) and at WAKO Pure Chemical Industries (Ogaki, Japan; n = 93) (Supplementary Figure 1). Available AFP data was ascertained at time of sample drawing for sAxl analysis and was available in n = 298 patients and n = 28 healthy subjects. All serum samples were collected prior to therapeutic intervention. All blood samples were centrifuged to prepare sera that were free of cellular components and stored at -80 °C until further processing.

In patients in whom liver biopsy was performed due to routine diagnostics, liver tissue samples were reviewed by two independent pathologists to confirm the stage of fibrosis in each sample. Fibrosis grading was performed according to METAVIR as appropriate (no fibrosis (F0), mild fibrosis (F1), moderate fibrosis (F2), advanced fibrosis (F3), or cirrhosis (F4)). HCCs were diagnosed according to non-invasive imaging criteria or by histology [7]. CCA was diagnosed based on histology.

The study was conducted in compliance with the Declaration of Helsinki and was approved by the responsible Ethical Committees of the study centers. Informed consent was obtained from all study participants prior to the performance of study related procedures. CLD was diagnosed by laboratory tests as well as by imaging studies such as US, magnetic resonance imaging, or computed tomography according to international standards. Healthy controls were recruited using a database of registered healthy controls. Subjects with alterations in liver serology or incomplete data, as well as other malignancies were excluded from the study (Supplementary Figure 1). Further clinical information of HCC patients concerning age, sex, hepatitis B virus (HBV) and hepatitis C virus (HCV) status, as well as cirrhosis, vascular invasion and lymph node metastasis was partially available (Table 1). Subjects were stratified on the basis of underlying liver disease, tumor staging and available AFP levels (Table 2). A cohort of HCC patients could be further classified by the Barcelona Clinic Liver Cancer (BCLC) classification into early (BCLC stage A; n = 45), intermediate (BCLC stage B; n = 45), advanced (BCLC stage C; n = 67) and end-stage HCC (BCLC stage D; n = 12).

Enzyme-linked immunosorbent assay

Solid phase sandwich ELISAs were carried out according to manufacturer’s protocol of ‘human Axl DuoSet® ELISAs’ (R&D Systems, Minneapolis, USA) including modifications for optimization of the assay [34]. These modifications resulted in higher detectable serum levels of sAxl as compared to our recent study [24]. Notably, these variations of sAxl concentrations in the serum were found to depend on the dilution medium and the factor of dilution [34]. Samples and detection antibody were diluted in LowCross-buffer® (Candor Bioscience, Wangen, Germany) instead of using Dulbecco’s phosphate buffered saline (DPBS) containing 1% bovine serum albumin (BSA). Briefly, a microtiter plate (96 well, high binding;
Greiner Bio-One, Frickenhausen, Germany) was coated overnight at room temperature (RT) with 2 µg/mL human Axl capture antibody diluted 1:180 in DPBS (PromoCell, Heidelberg, Germany). Afterwards, 3 washing steps with each 300 µL of DPBS, containing 0.05% Tween® 20 (AppliChem, Darmstadt, Germany) were carried out by utilizing a HydroSpeed™ plate washer (Tecan, Männedorf, Switzerland). The plate was blocked with 300 µL reagent diluent, phosphate buffered saline (PBS) containing 1% high grade BSA (Probumin®, Millipore, Illinois, USA), for 2 hours at RT. The washing steps were repeated and subsequently, 100 µL of recombinant Axl standards and samples, diluted 1:200, were added to the 96 well plates and incubated for 2 hours at RT. Mentioned washing steps were repeated followed by addition of 100 µL of 50 ng/mL human Axl biotinylated detection antibody, diluted 1:180 in LowCross-buffer® (Candor Bioscience, Wangen, Germany), to each well. After incubation for 2 hours at RT, the plates were washed again three times and 100 µL streptavidin-horseradish peroxidase working dilution was added per well. Dark incubation at RT for 20 minutes and three times washing with PBST prepared the plate for incubation with 100 µL of a 1:1 mixture of hydrogen peroxidase and tetramethylbenzidine (Substrate A and B, R&D Systems Minneapolis, USA) for further 15 minutes in the dark. Appearing enzymatic color reaction was finally stopped with 50 µL of 2 N sulfuric acid (Carl Roth, Karlsruhe, Germany). Subsequently, the optical density (OD) was determined at 450 nm using a microplate reader (Biochrom, Berlin, Germany) with a wavelength correction at 620 nm to correct for optical imperfections in the plate. On each plate, a separate seven-point standard curve was established with absorbance on the vertical axis and the concentrations on the horizontal axis. The serial dilutions of the recombinant Axl standard curve included 4.000, 2.000, 1.000, 500, 250, 125 and 62.5 pg/mL. LowCross-buffer® was used as a negative control. All samples were measured in biological replicates and technical triplicates.

Statistical analysis

Microsoft Excel 2010 (Microsoft, Redmond, USA), GraphPad Prism 5 (GraphPad Software, La Jolla, USA) in combination with IBM SPSS software v 20.0 (IBM Corp., Armonk, USA) was utilized for statistical analysis and continuous data comparison. Nonparametric, two-sided Mann-Whitney U tests were carried out for single comparisons. \( p \) values < 0.05, \( P < 0.01 \), or \( P < 0.001 \) were considered statistically significant.

Receiver operating characteristics

IBM SPSS software v 20.0 (IBM Corp., Armonk, USA) was used to plot sensitivity against false positive rate to generate receiver operating characteristics (ROC) curves. ROC curves were compiled using either sAxl or AFP alone or in combination. For evaluation of both biomarkers, a combinatorial variable was generated by binary logistic regression through an iterative maximum likelihood procedure. The diagnostic performance was evaluated by ROC curve analysis considering the area under the curve (AUC) with a 95% confidence interval (CI). Youden Index \( J \) calculation led to optimal cut-off values for sAxl selected at the concentrations representing the highest sum of sensitivity and specificity, respectively. In the case of AFP, the clinically established cutoff value of 20 ng/mL was applied [13, 35-38].

Cell culture

The hepatic myofibroblast cell lines MF-2, MF-5, MF-6, MF-7, MF-8, MF-9, and MF-10 [39], the mesenchymal and epithelial HCC cell lines (SNU449, HLF and HUH7, HepG2, respectively), as well as the CCA cell lines CCLP-1, B2/2 and B2/Tr [40] were cultured with appropriate ACL and RPMI media plus 10% fetal calf serum (FCS). B2/2 and B2/Tr cells were isolated from biopsies of CCA patients. Cells were authenticated by short tandem repeat analysis in July 2016. All cells were routinely screened for the absence of mycoplasma. After cells reached a confluence of about 80%, the FCS-rich media was removed and 1.5 mL serum-free RPMI was added to each cell line. Subsequently, cells were allowed to release sAxl into supernatants for 24 hours. Next, the supernatants were cleared from cell debris and analyzed for sAxl levels by ELISA. Finally, the cells were counted (CASY®, OLS OMNI Life Science, Bremen, Germany) after harvesting of cell supernatants to allow normalization of sAxl values to cell numbers.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

GRANT SUPPORT

This work was supported by the Austrian Science Fund, FWF, P25356 (to WM) and supported by funds of the Oesterreichische Nationalbank (Oesterreichische Nationalbank, Anniversary Fund, project number: 16673) (to WM).

REFERENCES

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007; 132:2557-2576.
2. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012; 379:1245-1255.
3. Ikai I, Kudo M, Arii S, Omata M, Kojiro M, Sakamoto M, Takayasu K, Hayashi N, Makuuchi M, Matsuyama Y,
4. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009; 27:1485-1491.

5. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso MdA, Sala M, Bru C, Rodés J, Bruix J. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999; 29:62-67.

6. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53:1020-1022.

7. European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012; 56:908-943.

8. Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, Marrero JA. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009; 30:37-47.

9. Paul SB, Gulati MS, Sreenivas V, Madan K, Gupta AK, Mukhopadhyay S, Acharya SK. Evaluating patients with cirrhosis for hepatocellular carcinoma: value of clinical symptomatology, imaging and alpha-fetoprotein. Oncology. 2007; 72:117-123.

10. Marrero JA, El-Serag HB. Alpha-fetoprotein should be included in the hepatocellular carcinoma surveillance guidelines of the American Association for the Study of Liver Diseases. Hepatology. 2011; 53:1060-1061; author reply 1061-1062.

11. Durazo FA, Blatt LM, Corey WG, Lin JH, Han S, Saab S, Busuttil RW, Tong MJ. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol. 2008; 23:1541-1548.

12. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, Reddy KR, Harnois D, Llovet JM, Normolle D, Dallgren J, Chia D, Lok AS, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009; 137:110-118.

13. Shen Q, Fan J, Yang XR, Tan Y, Zhao W, Xu Y, Wang N, Niu Y, Wu Z, Zhou J, Qiu SJ, Shi YH, Yu B, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol. 2012; 13:817-826.

14. Carr BI, Kanke F, Wise M, Satomura S. Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig Dis Sci. 2007; 52:776-782.

15. Reichl P, Mikulits W. Accuracy of novel diagnostic biomarkers for hepatocellular carcinoma: an update for clinicians. Oncol Rep. 2016; 36:613-625.

16. Ekman C, Stenhoff J, Dahlback B. Gas6 is complexed to the soluble tyrosine kinase receptor Axl in human blood. J Thromb Haemost. 2010; 8:838-844.

17. O’Bryan JP, Fridell YW, Koski R, Varnum B, Liu ET. The transforming receptor tyrosine kinase, Axl, is post-translationally regulated by proteolytic cleavage. J Biol Chem. 1995; 270:551-557.

18. Lemke G. Biology of the TAM receptors. Cold Spring Harb Perspect Biol. 2013; 5:a009076.

19. Ekman C, Site DF, Gottsater A, Lindblad B, Dahlback B. Plasma concentrations of growth arrest specific protein 6 and the soluble form of its tyrosine kinase receptor Axl as markers of large abdominal aortic aneurysms. Clin Biochem. 2010; 43:110-114.

20. Ekman C, Jonsen A, Sturfelt G, Bengtsson AA, Dahlback B. Plasma concentrations of Gas6 and sAxl correlate with disease activity in systemic lupus erythematosus. Rheumatology (Oxford). 2011; 50:1064-1069.

21. Zhu H, Sun X, Zhu L, Hu F, Shi L, Fan C, Li Z, Su Y. Different expression patterns and clinical significance of mAxl and sAxl in systemic lupus erythematosus. Lupus. 2014; 23:624-634.

22. Liu X, Gong Y, Jia J, Bai Y, Gui S, Wang T, Zhou R. Plasma concentrations of sAxl are associated with severe preeclampsia. Clin Biochem. 2014; 47:173-176.

23. Reichl P, Dengler M, van Zijl F, Huber H, Fuhrlinger G, Reichel C, Sieghart W, Peck-Radosavljevic M, Grubinger M, Mikulits W. Axl activates autocrine transforming growth factor-beta signaling in hepatocellular carcinoma. Hepatology. 2015; 61:930-941.

24. Reichl P, Fang M, Starlinger P, Stauffer K, Nenutil R, Muller P, Greplova K, Valik D, Dooley S, Brostjan C, Gruenberger T, Shen J, Man K, et al. Multicenter analysis of soluble Axl reveals diagnostic value for very early stage hepatocellular carcinoma. Int J Cancer. 2015; 137:385-394.

25. Barcena C, Stefanovic M, Tutasaus A, Joanna L, Menendez A, Garcia-Ruiz C, Sancho-Brul P, Mari M, Caballeria J, Rothlin CV, Fernandez-Checa JC, de Frutos PG, Morales A. Gas6/Axl pathway is activated in chronic liver disease and its targeting reduces fibrosis via hepatic stellate cell inactivation. J Hepatol. 2015; 63:670-678.

26. Lafidil F, Chobert MN, Couchie D, Brouillet A, Zafrañi ES, Mavri P, Laperche Y. Induction of Gas6 protein in CCl4-induced rat liver injury and anti-apoptotic effect on hepatic stellate cells. Hepatology. 2006; 44:228-239.

27. Fourcot A, Couchie D, Chobert MN, Zafrani ES, Mavier P, Laperche Y, Brouillet A. Gas6 deficiency prevents liver inflammation, steatohepatitis, and fibrosis in
mice. Am J Physiol Gastrointest Liver Physiol. 2011; 300:G1043-G1053.

28. Lafdi F, Chobert MN, Deveaux V, Zafrani ES, Mavier P, Nakano T, Lapercé Y, Brouillet A. Growth arrest-specific protein 6 deficiency impairs liver tissue repair after acute toxic hepatitis in mice. J Hepatol. 2009; 51:55-66.

29. Coulouarn C, Corlu A, Glaise D, Guenon I, Thorgeirsson SS, Clément B. Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma. Cancer Res. 2012; 72:2533-2542.

30. Okabe H, Hayashi H, Nakagawa S, Imai K, Nitta H, Arima K, Hashimoto D, Chikamoto A, Ishiko T, Beppu T, Baba H. Inducible factors for cancer-associated fibroblasts in liver cancer versus myofibroblasts in inflammatory liver disease. Histol Histopathol. 2016; 31:141-148.

31. Jang ES, Jeong SH, Kim JW, Choi YS, Leissner P, Brechot C. Diagnostic performance of alpha-fetoprotein, protein induced by Vitamin K absence, osteopontin, Dickkopf-1 and its combinations for hepatocellular carcinoma. PLoS One. 2016; 11:e0151069.

32. Sun Y, Gao G, Cai J, Wang Y, Qu X, He L, Liu F, Zhang Y, Lin K, Ma S, Yang X, Qian X, Zhao X. Annexin A2 is a discriminative serological candidate in early hepatocellular carcinoma. Carcinogenesis. 2013; 34:595-604.

33. Li J, Cheng ZJ, Liu Y, Yan ZL, Wang K, Wu D, Wan XY, Xia Y, Lau WY, Wu MC, Shen F. Serum thioredoxin is a diagnostic marker for hepatocellular carcinoma. Oncotarget. 2015; 6:9551-9563. doi: 10.18632/oncotarget.3314.

34. Dengler M, Huber H, Müller CJ, Zellmer A, Rauch P, Mikulits W. Accurate determination of soluble Axl by enzyme linked immunosorbent assay. Assay Drug Dev Technol. 2016; 14:543-550.

35. Trevisani F, D’Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, Domenicali M, De Notariis S, Roda E, Bernardi M. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 2001; 34:570-575.

36. El-Serag HB, Davila JA. Surveillance for hepatocellular carcinoma: in whom and how? Therap Adv Gastroenterol. 2011; 4:5-10.

37. da Costa AN, Plymoth A, Santos-Silva D, Ottiz-Cuanan S, Camey S, Guilloreau P, Sangrajrang S, Khuhaprema T, Mendy M, Lesi OA, Chang HK, Oh JK, Lee DH, et al. Osteopontin and latent-TGF beta binding-protein 2 as potential diagnostic markers for HBV-related hepatocellular carcinoma. Int J Cancer. 2015; 136:172-181.

38. Zhou L, Rui JA, Wang SB, Chen SG, Qu Q. The significance of serum AFP cut-off values, 20 and 400 ng/mL in curatively resected patients with hepatocellular carcinoma and cirrhosis might be of difference. Hepatogastroenterology. 2012; 59:840-843.

39. Sagmeister S, Eisenbauer M, Pirker C, Mohr T, Holzmann K, Zwickl H, Bichler C, Kandioler D, Wrba F, Mikulits W, Gerner C, Shehata M, Majdic O, et al. New cellular tools reveal complex epithelial-mesenchymal interactions in hepatocarcinogenesis. Br J Cancer. 2008; 99:151-159.

40. Shimizu Y, Demetris AJ, Gollin SM, Storto PD, Bedford HM, Altarac S, lwatsuki S, Herberman RB, Whiteside TL. Two new human cholangiocarcinoma cell lines and their cytotogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells. Int J Cancer. 1992; 52:252-260.